Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

Withdrawn before enrolling · Phase 1

Conditions studied: Sarcoma, Soft Tissue

In brief

Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue, and failure to surgically remove a cancer-affected lymph node or residual cancer at the surgical margin reduces a patient's chance of survival. Moreover, damage to adjacent normal tissue during surgery can result in significant morbidity. The investigators hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as they operate. This is a safety study to assess the safety of BLZ-100 in patients with soft tissue sarcoma undergoing surgery.

Key facts

Study ID

NCT02464332

Run by

Blaze Bioscience Inc.

People needed

0

Starts

2015-09-01

Expected to finish

2016-05-01

Last updated by the study team

2016-05-26

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male of female subject aged 18-75 years
• Diagnosis of soft tissue sarcoma, with scheduled surgical removal for treatment for the disease and completion of chemotherapy or radiation within 4 weeks of BLZ-100 administration
• Able to provide written informed consent
• If of child-bearing potential, agree to continued use of two reliable methods of contraceptive from study entry (time of informed consent) through 30 days after BLZ-100 administration
• Available for all study visits and able to comply with all study requirements

You may not qualify if…

• Clinically-suspected and/or pathologically-confirmed sarcoma of the bone (e.g. osteosarcoma, Ewing's sarcoma with bony involvement, chondrosarcoma, Kaposi's sarcoma, extraosseous primitive neuroectodermal tumor [PNET])
• Evidence of metastatic disease
• Female who is lactating/breastfeeding
• Female with a positive pregnancy test or who is planning to become pregnant during the duration of the study
• Karnofsky Performance Status of <60%
• Any of the following laboratory abnormalities at Screening:
• Neutrophil count <1.5 x 10\^9/L
• Platelets <75 x 10\^9/L
• Hemoglobin <10 g/dL (may be determined following transfusion)
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3x upper limit of normal (ULN)
• Total bilirubin >1.5x upper limit of reference range (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction)
• Internal Normalized Ratio (INR) >1.5
• Creatinine >1.5x ULN
• Calculated estimated glomerular filtration rate (eGFR) ≤60 mL/min
• Positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)
• QTc prolongation >450 msec
• History of hypersensitivity or allergic reactions requiring corticosteroids, epinephrine, and/or hospitalization
• Uncontrolled asthma or asthma requiring oral corticosteroids
• Known or suspected sensitivity to imaging agents that may be used in clinical assessment of this study
• Known or suspected sensitivity to indocyanine green (ICG)
• Unstable angina, myocardial infarction, known or suspected transient ischemic events, or stroke within 24 weeks of start of Screening
• Uncontrolled hypertension
• Initiation of new photosensitizing drugs within 30 days of Screening
• Use of any ongoing medications, which might generate fluorescence or, according to the medication label, might generate a photochemical reaction. These include haematoporphyrin derivatives and purified fractions, Photofrin®, and the precursors of protoporphyrin IX (5-Aminolevulinic acid) used in Gliolan or Hexvix
• Receipt of an investigational drug or device within 30 days of enrollment

Where it is running

• Cedars-Sinai Medical Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.